Oncimmune Gets Medicare Reimbursement for Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer detection company Oncimmune today said that it has received Medicare coverage for a new blood-based test that it claims can detect cancers as much as five year earlier than current testing methods.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.